Company Overview of Source Precision Medicine, Inc.

Company Overview

Source Precision Medicine, Inc., doing business as Source MDx, engages in developing and commercializing RNA transcript-based prognostic, predictive, and early detection molecular diagnostic assays and tests for cancer and other inflammatory diseases. It develops an integrated molecular diagnostic system, which includes quantitative polymerase chain reaction assays, target specific gene expression ranges, and latent class and proprietary enumeration methodologies that measure vital signs of the cell. The company also develops molecular diagnostics for various cancers, including lung and melanoma, as well as for certain inflammatory, cardiovascular, infectious, and autoimmune diseases, such a...

Source Precision Medicine, Inc., doing business as Source MDx, engages in developing and commercializing RNA transcript-based prognostic, predictive, and early detection molecular diagnostic assays and tests for cancer and other inflammatory diseases. It develops an integrated molecular diagnostic system, which includes quantitative polymerase chain reaction assays, target specific gene expression ranges, and latent class and proprietary enumeration methodologies that measure vital signs of the cell. The company also develops molecular diagnostics for various cancers, including lung and melanoma, as well as for certain inflammatory, cardiovascular, infectious, and autoimmune diseases, such as multiple sclerosis. Its assays and tests measure RNA-transcript-based gene expression in whole blood using quantitative polymerase chain reaction optimized for clinical use in a commercial setting. The company was founded in 1998 and is headquartered in Boulder, Colorado with an additional office in Newton, Massachusetts.

Key Executives for Source Precision Medicine, Inc.

Similar Private Companies By Industry

Recent Private Companies Transactions